HiFiBiO Therapeutics CEO Liang Schweizer Receives 2020 Extraordinary Women Advancing Healthcare Award

The Commonwealth Institute Recognizes Women Leaders in Massachusetts Demonstrating Impact, Inspiration, and Innovation across Healthcare Industry

CAMBRIDGE, Mass., – September 24, 2020HiFiBiO Therapeutics today announced its CEO, Liang Schweizer, PhD, has been recognized with an Extraordinary Women Advancing Healthcare Award (EWAH) by The Commonwealth Institute (TCI), the leading nonprofit organization devoted to advancing all women leaders. The EWAH award is the first of its kind to recognize and celebrate remarkable healthcare leaders in Massachusetts for their outstanding career achievements and impact.

Dr. Schweizer was selected as one of the 10 recipients for her impact in advancing healthcare innovation, inspiration in leading others, and commitment to fostering diversity. As CEO of HiFiBiO Therapeutics, she has built a multi-national team of pioneering scientists and business professionals who are executing an open innovation strategy, which combines the company’s immune-modulation expertise with external partnerships to develop and deliver high-quality biotherapeutics to patients. Her leadership has recently been highlighted by the exceptional progress in the discovery and development of a neutralizing antibody for COVID-19 patients. The project started with multiple collaborations and rapidly progressed to IND filing in six months. Now the team is conducting a Phase I clinical trial for this antibody (HFB30132A) and hopes to deliver it to patients as soon as possible.

“I can think of no other extraordinary female leader more deserving of this award than Dr. Schweizer,” said Pauline Jen Ryan, Partner at Red Sky Partners, who nominated Dr. Schweizer for the award. “Her entire career has been built on a foundation of scientific innovation and inspirational leadership at large pharmaceutical companies such as Bristol Myers Squibb and Sanofi, as well as at emerging multinational biotech companies like HiFiBiO Therapeutics. I am extremely confident that HiFiBiO will be able to deliver innovative treatments to patients worldwide due to Dr. Schweizer’s unrelenting focus on scientific excellence, belief in mentoring, empowerment of others, and commitment to diversity.”

“The Commonwealth of Massachusetts is a global leader in the healthcare industry so it is fitting that The Commonwealth Institute – an organization founded over 24 years ago to help women leaders in Massachusetts achieve greater success – would celebrate and honor emerging women leaders in the industry,” said Elizabeth L. Hailer, Executive Director of The Commonwealth Institute and EWAH Co-Chair. “This award is a testament to the dedication, innovation, and influence of each of these extraordinary women leaders.”

The virtual award ceremony will take place on September 24, 2020. A full list of the EWAH winners can be found here.

About the Commonwealth Institute

The Commonwealth Institute (TCI) is a non-profit organization that works with women CEOs, corporate executives, entrepreneurs, sole proprietors, and the rising generation of women leaders to help them build successful businesses, organizations, and careers. In short, TCI helps women in business achieve greater success! For 24 years, The Commonwealth Institute has provided a variety of opportunities to help women succeed on a personal and professional level while propelling their organizations forward.

About HiFiBiO Therapeutics

HiFiBiO Therapeutics is transforming the field of immunotherapy by combining proprietary single-cell profiling technologies with advanced data intelligence and deep knowledge of immune system biology. This approach enables the development of novel antibody therapies that are paired with biomarkers to predict patient response. HiFiBiO Therapeutics is working actively to address unmet medical needs around the world through its own innovative pipeline programs and open-innovation partnerships with world-renowned industry and academic researchers. The company’s strong global footprint features cutting-edge laboratories on three continents, in Cambridge, Mass., Paris, Shanghai and Hong Kong. To learn more, please visit

HiFiBiO® and DIS® are trademarks of HiFiBiO and its affiliates.